{"id":"https://openalex.org/W2016511744","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0868","title":"Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers","display_name":"Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers","publication_year":2014,"publication_date":"2014-09-19","ids":{"openalex":"https://openalex.org/W2016511744","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0868","mag":"2016511744","pmid":"https://pubmed.ncbi.nlm.nih.gov/25239610","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/4233149"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.ccr-14-0868","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0868","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-14-0868","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4233149","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5068368047","display_name":"Timothy Anthony Yap","orcid":"https://orcid.org/0000-0002-2154-3309","observed_orcids":["https://orcid.org/0000-0002-2154-3309"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Timothy A. Yap","raw_affiliation_strings":["1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100662545","display_name":"Yan Li","orcid":"https://orcid.org/0000-0001-5723-6936","observed_orcids":["https://orcid.org/0000-0001-5723-6936"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Li Yan","raw_affiliation_strings":["3Merck & Co., Inc., Whitehouse Station, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Merck & Co., Inc., Whitehouse Station, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070570779","display_name":"Amita Patnaik","orcid":"https://orcid.org/0000-0002-4144-2193","observed_orcids":["https://orcid.org/0000-0002-4144-2193"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amita Patnaik","raw_affiliation_strings":["4South Texas Accelerated Research Therapeutics, San Antonio, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4South Texas Accelerated Research Therapeutics, San Antonio, Texas","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056339622","display_name":"Nina Tunariu","orcid":"https://orcid.org/0000-0001-6656-3699","observed_orcids":["https://orcid.org/0000-0001-6656-3699"]},"institutions":[{"id":"https://openalex.org/I1299528221","display_name":"Engineering and Physical Sciences Research Council","ror":"https://ror.org/0439y7842","country_code":"GB","type":"government","lineage":["https://openalex.org/I1299528221","https://openalex.org/I4210087105"]},{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nina Tunariu","raw_affiliation_strings":["5CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1299528221","https://openalex.org/I1325846038","https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102958335","display_name":"Andrea Biondo","orcid":"https://orcid.org/0000-0003-0599-254X","observed_orcids":["https://orcid.org/0000-0003-0599-254X"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrea Biondo","raw_affiliation_strings":["1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028599834","display_name":"Ivy Fearen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ivy Fearen","raw_affiliation_strings":["3Merck & Co., Inc., Whitehouse Station, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Merck & Co., Inc., Whitehouse Station, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022467575","display_name":"Kyriakos P. Papadopoulos","orcid":"https://orcid.org/0000-0002-0667-2620","observed_orcids":["https://orcid.org/0000-0002-0667-2620"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kyriakos P. Papadopoulos","raw_affiliation_strings":["4South Texas Accelerated Research Therapeutics, San Antonio, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4South Texas Accelerated Research Therapeutics, San Antonio, Texas","institution_ids":["https://openalex.org/I4210119066"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072116005","display_name":"David Olmos","orcid":"https://orcid.org/0000-0002-7003-4826","observed_orcids":["https://orcid.org/0000-0002-7003-4826"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"David Olmos","raw_affiliation_strings":["1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080215197","display_name":"Richard D. Baird","orcid":"https://orcid.org/0000-0001-7071-6483","observed_orcids":["https://orcid.org/0000-0001-7071-6483"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Richard Baird","raw_affiliation_strings":["1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113574602","display_name":"Liliana Delgado","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Liliana Delgado","raw_affiliation_strings":["3Merck & Co., Inc., Whitehouse Station, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Merck & Co., Inc., Whitehouse Station, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012970737","display_name":"Ernestina Tetteh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ernestina Tetteh","raw_affiliation_strings":["3Merck & Co., Inc., Whitehouse Station, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Merck & Co., Inc., Whitehouse Station, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027438799","display_name":"Robert A. Beckman","orcid":"https://orcid.org/0000-0003-0098-9210","observed_orcids":["https://orcid.org/0000-0003-0098-9210"]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert A. Beckman","raw_affiliation_strings":["3Merck & Co., Inc., Whitehouse Station, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Merck & Co., Inc., Whitehouse Station, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045593405","display_name":"Lisa C. Lupinacci","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1285764155","display_name":"Merck & Co., Inc., Rahway, NJ, USA (United States)","ror":"https://ror.org/02891sr49","country_code":"US","type":"company","lineage":["https://openalex.org/I1285764155"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Lisa Lupinacci","raw_affiliation_strings":["3Merck & Co., Inc., Whitehouse Station, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Merck & Co., Inc., Whitehouse Station, New Jersey","institution_ids":["https://openalex.org/I1285764155"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066136399","display_name":"Ruth Riisnaes","orcid":"https://orcid.org/0000-0002-8924-302X","observed_orcids":["https://orcid.org/0000-0002-8924-302X"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Ruth Riisnaes","raw_affiliation_strings":["2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045955939","display_name":"Shaun Decordova","orcid":"https://orcid.org/0000-0002-0091-0587","observed_orcids":["https://orcid.org/0000-0002-0091-0587"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Shaun Decordova","raw_affiliation_strings":["2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021741085","display_name":"Simon P. Heaton","orcid":"https://orcid.org/0000-0001-8438-2736","observed_orcids":["https://orcid.org/0000-0001-8438-2736"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Simon P. Heaton","raw_affiliation_strings":["2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5009096434","display_name":"Karen E. Swales","orcid":"https://orcid.org/0000-0002-6572-1293","observed_orcids":["https://orcid.org/0000-0002-6572-1293"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Karen Swales","raw_affiliation_strings":["2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060445631","display_name":"Nandita M. deSouza","orcid":"https://orcid.org/0000-0003-4232-476X","observed_orcids":["https://orcid.org/0000-0003-4232-476X"]},"institutions":[{"id":"https://openalex.org/I1299528221","display_name":"Engineering and Physical Sciences Research Council","ror":"https://ror.org/0439y7842","country_code":"GB","type":"government","lineage":["https://openalex.org/I1299528221","https://openalex.org/I4210087105"]},{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Nandita M. deSouza","raw_affiliation_strings":["5CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1299528221","https://openalex.org/I1325846038","https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068130659","display_name":"Martin O. Leach","orcid":"https://orcid.org/0000-0002-0756-5368","observed_orcids":["https://orcid.org/0000-0002-0756-5368"]},"institutions":[{"id":"https://openalex.org/I1299528221","display_name":"Engineering and Physical Sciences Research Council","ror":"https://ror.org/0439y7842","country_code":"GB","type":"government","lineage":["https://openalex.org/I1299528221","https://openalex.org/I4210087105"]},{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin O. Leach","raw_affiliation_strings":["5CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"5CR-UK and EPSRC Cancer Imaging Centre, Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1299528221","https://openalex.org/I1325846038","https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015193618","display_name":"Michelle Dawn Garrett","orcid":"https://orcid.org/0000-0002-3939-1673","observed_orcids":["https://orcid.org/0000-0002-3939-1673"]},"institutions":[{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Michelle D. Garrett","raw_affiliation_strings":["2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102841436","display_name":"Daniel M. Sullivan","orcid":"https://orcid.org/0009-0003-0951-9781","observed_orcids":["https://orcid.org/0009-0003-0951-9781","https://orcid.org/0000-0002-2183-1773"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel M. Sullivan","raw_affiliation_strings":["6H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"6H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072378199","display_name":"Johann Sebastian De Bono","orcid":"https://orcid.org/0000-0002-2034-595X","observed_orcids":["https://orcid.org/0000-0002-2034-595X"]},"institutions":[{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I142947616","display_name":"Institute of Cancer Research","ror":"https://ror.org/043jzw605","country_code":"GB","type":"education","lineage":["https://openalex.org/I124357947","https://openalex.org/I142947616"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Johann S. de Bono","raw_affiliation_strings":["1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom","institution_ids":["https://openalex.org/I1325846038"]},{"raw_affiliation_string":"2Division of Clinical Studies, The Institute of Cancer Research, Surrey, United Kingdom","institution_ids":["https://openalex.org/I142947616"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5060992997","display_name":"Anthony W. Tolcher","orcid":"https://orcid.org/0000-0002-6322-9721","observed_orcids":["https://orcid.org/0000-0002-6322-9721"]},"institutions":[{"id":"https://openalex.org/I4210119066","display_name":"South Texas Accelerated Research Therapeutics","ror":"https://ror.org/01scs7915","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210119066"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony W. Tolcher","raw_affiliation_strings":["4South Texas Accelerated Research Therapeutics, San Antonio, Texas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4South Texas Accelerated Research Therapeutics, San Antonio, Texas","institution_ids":["https://openalex.org/I4210119066"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":6,"corresponding_author_ids":["https://openalex.org/A5072378199"],"corresponding_institution_ids":["https://openalex.org/I1325846038","https://openalex.org/I142947616"],"apc_list":null,"apc_paid":null,"fwci":3.6876,"has_fulltext":false,"cited_by_count":81,"citation_normalized_percentile":{"value":0.94284086,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":99},"biblio":{"volume":"20","issue":"22","first_page":"5672","last_page":"5685"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10522","display_name":"Medical Imaging Techniques and Applications","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mk-2206","display_name":"MK-2206","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pan-akt-inhibitor","display_name":"pan-AKT inhibitor","score":0.7770000100135803},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.7649999856948853},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.8740000128746033},{"id":"https://openalex.org/keywords/pharmacodynamic-markers","display_name":"pharmacodynamic biomarkers","score":0.7609999775886536},{"id":"https://openalex.org/keywords/platelet-rich-plasma","display_name":"platelet-rich plasma","score":0.9160000085830688},{"id":"https://openalex.org/keywords/fmri","display_name":"functional MRI","score":0.7139999866485596},{"id":"https://openalex.org/keywords/dynamic-contrast-enhanced-mri","display_name":"dynamic contrast-enhanced MRI","score":0.8669999837875366},{"id":"https://openalex.org/keywords/diffusion-weighted-imaging","display_name":"diffusion-weighted imaging","score":0.9869999885559082},{"id":"https://openalex.org/keywords/magnetic-resonance-spectroscopy","display_name":"magnetic resonance spectroscopy","score":0.9739999771118164},{"id":"https://openalex.org/keywords/ovarian-cancer","display_name":"ovarian cancer","score":0.8799999952316284},{"id":"https://openalex.org/keywords/castration-resistant-prostate-cancer","display_name":"castration-resistant prostate cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.906000018119812},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.6420000195503235}],"concepts":[{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.7581270933151245},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7534804344177246},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.6764247417449951},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.6280565857887268},{"id":"https://openalex.org/C2778570526","wikidata":"https://www.wikidata.org/wiki/Q653197","display_name":"Rash","level":2,"score":0.6190919280052185},{"id":"https://openalex.org/C2780192828","wikidata":"https://www.wikidata.org/wiki/Q181257","display_name":"Prostate cancer","level":3,"score":0.4964805245399475},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.42737898230552673},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4199722409248352},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.39256808161735535}],"mesh":[{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D003952","descriptor_name":"Diagnostic Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D006575","descriptor_name":"Heterocyclic Compounds, 3-Ring","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008279","descriptor_name":"Magnetic Resonance Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009367","descriptor_name":"Neoplasm Staging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016903","descriptor_name":"Drug Monitoring","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020714","descriptor_name":"Maximum Tolerated Dose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D051057","descriptor_name":"Proto-Oncogene Proteins c-akt","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1158/1078-0432.ccr-14-0868","doi":"https://doi.org/10.1158/1078-0432.ccr-14-0868","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1078-0432.ccr-14-0868","pdf_url":null,"source":{"id":"https://openalex.org/S183149254","display_name":"Clinical Cancer Research","issn_l":"1078-0432","issn":["1078-0432","1557-3265"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Cancer Research","raw_type":"journal-article"},{"id":"pmid:25239610","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25239610","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical cancer research : an official journal of the American Association for Cancer Research","raw_type":"Clinical Trial, Phase I"},{"id":"pmh:oai:europepmc.org:3399151","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4233149","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:4233149","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4233149","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Clin Cancer Res","raw_type":"Text"},{"id":"pmh:oai:www.repository.cam.ac.uk:1810/246604","doi":null,"is_oa":false,"landing_page_url":"https://www.repository.cam.ac.uk/handle/1810/246604","pdf_url":null,"source":{"id":"https://openalex.org/S4306401777","display_name":"Apollo (University of Cambridge)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I241749","host_organization_name":"University of Cambridge","host_organization_lineage":["https://openalex.org/I241749"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Article"},{"id":"pmh:oai:kar.kent.ac.uk:54928","doi":null,"is_oa":false,"landing_page_url":"https://kar.kent.ac.uk/54928/","pdf_url":null,"source":{"id":"https://openalex.org/S4377196264","display_name":"Kent Academic Repository (University of Kent)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I20581793","host_organization_name":"University of Kent","host_organization_lineage":["https://openalex.org/I20581793"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Article"}],"best_oa_location":{"id":"pmh:oai:europepmc.org:3399151","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/4233149","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"Text"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/3","score":0.8100000023841858,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[{"id":"https://openalex.org/G292748385","display_name":null,"funder_award_id":"17782","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G3405356239","display_name":null,"funder_award_id":"AMS-SGCL10-Yap","funder_id":"https://openalex.org/F4320320241","funder_display_name":"Academy of Medical Sciences"},{"id":"https://openalex.org/G4276857719","display_name":null,"funder_award_id":"A15573","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"},{"id":"https://openalex.org/G4968764162","display_name":null,"funder_award_id":"CL-2012-22-001","funder_id":"https://openalex.org/F4320319990","funder_display_name":"National Institute for Health and Care Research"},{"id":"https://openalex.org/G7153462893","display_name":"NIHR Senior Investigator Award","funder_award_id":"NF-SI-0512-10162","funder_id":"https://openalex.org/F4320319990","funder_display_name":"National Institute for Health and Care Research"},{"id":"https://openalex.org/G8801512839","display_name":null,"funder_award_id":"16464","funder_id":"https://openalex.org/F4320319985","funder_display_name":"Cancer Research UK"}],"funders":[{"id":"https://openalex.org/F4320319985","display_name":"Cancer Research UK","ror":"https://ror.org/054225q67"},{"id":"https://openalex.org/F4320319990","display_name":"National Institute for Health and Care Research","ror":"https://ror.org/0187kwz08"},{"id":"https://openalex.org/F4320320241","display_name":"Academy of Medical Sciences","ror":"https://ror.org/00c489v88"}],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":38,"referenced_works":["https://openalex.org/W1594020010","https://openalex.org/W1676308325","https://openalex.org/W1933741927","https://openalex.org/W1966956946","https://openalex.org/W1977267072","https://openalex.org/W1979909416","https://openalex.org/W1995579320","https://openalex.org/W1997611659","https://openalex.org/W1999065747","https://openalex.org/W2006771504","https://openalex.org/W2018825426","https://openalex.org/W2027114592","https://openalex.org/W2053521827","https://openalex.org/W2060549297","https://openalex.org/W2070580351","https://openalex.org/W2076668534","https://openalex.org/W2087012714","https://openalex.org/W2088561077","https://openalex.org/W2088795063","https://openalex.org/W2097773105","https://openalex.org/W2106230346","https://openalex.org/W2107633226","https://openalex.org/W2112911113","https://openalex.org/W2119754956","https://openalex.org/W2125671174","https://openalex.org/W2128868545","https://openalex.org/W2129171769","https://openalex.org/W2139248078","https://openalex.org/W2148968740","https://openalex.org/W2149783293","https://openalex.org/W2150374672","https://openalex.org/W2155679349","https://openalex.org/W2156272715","https://openalex.org/W2165404212","https://openalex.org/W2167162853","https://openalex.org/W2590651193","https://openalex.org/W2590673385","https://openalex.org/W4242522656"],"related_works":["https://openalex.org/W2589824760","https://openalex.org/W2100263195","https://openalex.org/W2590406220","https://openalex.org/W2520717841","https://openalex.org/W2025587649","https://openalex.org/W2027114592","https://openalex.org/W3000587020","https://openalex.org/W3080988173","https://openalex.org/W1167827059","https://openalex.org/W2795332556"],"abstract_inverted_index":{"PURPOSE:":[0],"Multiple":[1],"cancers":[2,58,96,101],"harbor":[3],"genetic":[4],"aberrations":[5],"that":[6,215],"impact":[7],"AKT":[8,188,237],"signaling.":[9],"MK-2206":[10,41,85,136,141,154,202,232,258],"is":[11,252],"a":[12,17,33,38,62,225],"potent":[13],"pan-AKT":[14],"inhibitor":[15],"with":[16,56,91,99,178,193,231],"maximum":[18],"tolerated":[19,175],"dose":[20,247],"(MTD)":[21],"previously":[22],"established":[23,157],"at":[24,142,158,164],"60":[25,134],"mg":[26,135,150,160,250],"on":[27],"alternate":[28],"days":[29],"(QOD).":[30],"Due":[31],"to":[32,45,68,172,176],"long":[34],"half-life":[35],"(60-80":[36],"hours),":[37],"weekly":[39],"(QW)":[40],"schedule":[42],"was":[43,86,156,191],"pursued":[44],"compare":[46],"intermittent":[47,198,246],"QW":[48,63,153,169,199,243,251],"and":[49,72,77,93,97,119,148,166,185,197,207,242,260],"continuous":[50,195],"QOD":[51,82,196,241],"dosing.":[52],"EXPERIMENTAL":[53],"DESIGN:":[54],"Patients":[55],"advanced":[57,100],"were":[59,129],"enrolled":[60],"in":[61,89,203,224,235,240,255],"dose-escalation":[64],"phase":[65,226,256],"I":[66,227],"study":[67],"investigate":[69],"the":[70],"safety":[71],"pharmacokinetic-pharmacodynamic":[73],"profiles":[74],"of":[75,84,126,201,248],"tumor":[76,206],"platelet-rich":[78],"plasma":[79],"(PRP).":[80],"The":[81,152,210,245],"MTD":[83,155],"also":[87],"assessed":[88],"patients":[90,98,128,132],"ovarian":[92],"castration-resistant":[94],"prostate":[95],"undergoing":[102],"multiparametric":[103,217],"functional":[104,211],"magnetic":[105,116],"resonance":[106,117],"imaging":[107,212],"(MRI)":[108],"studies,":[109],"including":[110,180],"dynamic":[111],"contrast-enhanced":[112],"MRI,":[113],"diffusion-weighted":[114],"imaging,":[115],"spectroscopy,":[118],"intrinsic":[120],"susceptibility-weighted":[121],"MRI.":[122],"RESULTS:":[123],"A":[124],"total":[125],"71":[127],"enrolled;":[130],"38":[131],"had":[133],"QOD,":[137,177],"whereas":[138],"33":[139],"received":[140],"90,":[143],"135,":[144],"150,":[145],"200,":[146],"250,":[147],"300":[149,167],"QW.":[151],"200":[159,249],"following":[161],"dose-limiting":[162],"rash":[163],"250":[165],"mg.":[168],"dosing":[170,200],"appeared":[171],"be":[173,221],"similarly":[174],"toxicities":[179],"rash,":[181],"gastrointestinal":[182],"symptoms,":[183],"fatigue,":[184],"hyperglycemia.":[186],"Significant":[187],"pathway":[189,238],"blockade":[190,239],"observed":[192],"both":[194],"serially":[204],"obtained":[205],"PRP":[208],"specimens.":[209],"studies":[213,262],"demonstrated":[214],"complex":[216],"MRI":[218],"protocols":[219],"may":[220],"effectively":[222],"implemented":[223],"trial.":[228],"CONCLUSIONS:":[229],"Treatment":[230],"safely":[233],"results":[234],"significant":[236],"schedules.":[244],"currently":[253],"used":[254],"II":[257],"monotherapy":[259],"combination":[261],"(NCT00670488).":[263]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":3},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":11},{"year":2019,"cited_by_count":8},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":9},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}